Financhill
Buy
57

CTOR Quote, Financials, Valuation and Earnings

Last price:
$1.54
Seasonality move :
-41.24%
Day range:
$1.23 - $1.47
52-week range:
$0.55 - $49.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.91x
Volume:
1.3M
Avg. volume:
558.7K
1-year change:
-87.22%
Market cap:
$103.8M
Revenue:
--
EPS (TTM):
-$0.33

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CTOR
Citius Oncology
$5.7M -- -- -- $3.00
CTXR
Citius Pharmaceuticals
-- $0.11 -- -75.33% $6.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CTOR
Citius Oncology
$1.45 $3.00 $103.8M -- $0.00 0% --
CTXR
Citius Pharmaceuticals
$0.85 $6.00 $8.8M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.62 $0.85 $3.6M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.34 -- $21.5M -- $0.00 0% --
OGEN
Oragenics
$4.37 $1.00 $3.1M -- $0.00 0% 1.40x
TOVX
Theriva Biologics
$0.47 $7.00 $3.8M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CTOR
Citius Oncology
-- -0.823 -- --
CTXR
Citius Pharmaceuticals
-- -2.175 -- --
NBY
NovaBay Pharmaceuticals
4.54% -0.941 1.51% 0.75x
NNVC
Nanoviricides
-- -0.642 -- --
OGEN
Oragenics
-- -1.150 -- --
TOVX
Theriva Biologics
-- -3.651 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CTOR
Citius Oncology
-- -$7.5M -- -- -- --
CTXR
Citius Pharmaceuticals
-- -$11.3M -- -- -- -$4.5M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Citius Oncology vs. Competitors

  • Which has Higher Returns CTOR or CTXR?

    Citius Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Citius Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTOR
    Citius Oncology
    -- -$0.11 --
    CTXR
    Citius Pharmaceuticals
    -- -$1.27 --
  • What do Analysts Say About CTOR or CTXR?

    Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 106.9%. On the other hand Citius Pharmaceuticals has an analysts' consensus of $6.00 which suggests that it could grow by 603.15%. Given that Citius Pharmaceuticals has higher upside potential than Citius Oncology, analysts believe Citius Pharmaceuticals is more attractive than Citius Oncology.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTOR
    Citius Oncology
    0 1 0
    CTXR
    Citius Pharmaceuticals
    1 1 0
  • Is CTOR or CTXR More Risky?

    Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Pharmaceuticals has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.206%.

  • Which is a Better Dividend Stock CTOR or CTXR?

    Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Citius Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTOR or CTXR?

    Citius Oncology quarterly revenues are --, which are smaller than Citius Pharmaceuticals quarterly revenues of --. Citius Oncology's net income of -$7.7M is higher than Citius Pharmaceuticals's net income of -$10.9M. Notably, Citius Oncology's price-to-earnings ratio is -- while Citius Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus -- for Citius Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTOR
    Citius Oncology
    -- -- -- -$7.7M
    CTXR
    Citius Pharmaceuticals
    -- -- -- -$10.9M
  • Which has Higher Returns CTOR or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of -49.65%. Citius Oncology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTOR
    Citius Oncology
    -- -$0.11 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About CTOR or NBY?

    Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 106.9%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 37.5%. Given that Citius Oncology has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Oncology is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTOR
    Citius Oncology
    0 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is CTOR or NBY More Risky?

    Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

  • Which is a Better Dividend Stock CTOR or NBY?

    Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTOR or NBY?

    Citius Oncology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Oncology's net income of -$7.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Citius Oncology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTOR
    Citius Oncology
    -- -- -- -$7.7M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns CTOR or NNVC?

    Nanoviricides has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTOR
    Citius Oncology
    -- -$0.11 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About CTOR or NNVC?

    Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 106.9%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 385.08%. Given that Nanoviricides has higher upside potential than Citius Oncology, analysts believe Nanoviricides is more attractive than Citius Oncology.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTOR
    Citius Oncology
    0 1 0
    NNVC
    Nanoviricides
    0 0 0
  • Is CTOR or NNVC More Risky?

    Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

  • Which is a Better Dividend Stock CTOR or NNVC?

    Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTOR or NNVC?

    Citius Oncology quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Citius Oncology's net income of -$7.7M is lower than Nanoviricides's net income of -$2.2M. Notably, Citius Oncology's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTOR
    Citius Oncology
    -- -- -- -$7.7M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns CTOR or OGEN?

    Oragenics has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTOR
    Citius Oncology
    -- -$0.11 --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About CTOR or OGEN?

    Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 106.9%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 586.57%. Given that Oragenics has higher upside potential than Citius Oncology, analysts believe Oragenics is more attractive than Citius Oncology.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTOR
    Citius Oncology
    0 1 0
    OGEN
    Oragenics
    0 1 0
  • Is CTOR or OGEN More Risky?

    Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

  • Which is a Better Dividend Stock CTOR or OGEN?

    Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTOR or OGEN?

    Citius Oncology quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Citius Oncology's net income of -$7.7M is lower than Oragenics's net income of -$2.2M. Notably, Citius Oncology's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTOR
    Citius Oncology
    -- -- -- -$7.7M
    OGEN
    Oragenics
    1.40x -- -- -$2.2M
  • Which has Higher Returns CTOR or TOVX?

    Theriva Biologics has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTOR
    Citius Oncology
    -- -$0.11 --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About CTOR or TOVX?

    Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 106.9%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1398.61%. Given that Theriva Biologics has higher upside potential than Citius Oncology, analysts believe Theriva Biologics is more attractive than Citius Oncology.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTOR
    Citius Oncology
    0 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is CTOR or TOVX More Risky?

    Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

  • Which is a Better Dividend Stock CTOR or TOVX?

    Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTOR or TOVX?

    Citius Oncology quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Citius Oncology's net income of -$7.7M is lower than Theriva Biologics's net income of -$4.3M. Notably, Citius Oncology's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTOR
    Citius Oncology
    -- -- -- -$7.7M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

AMC Stock Forecast, How High Could It Go in 2025 and Beyond?
AMC Stock Forecast, How High Could It Go in 2025 and Beyond?

AMC Entertainment (NYSE:AMC) has been rising lately after years of…

Where Will Reddit Stock Be In 5 Years?
Where Will Reddit Stock Be In 5 Years?

On a wet March morning last year, the famously orange…

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
47
RGC alert for Jun 18

Regencell Bioscience Holdings [RGC] is down 20.31% over the past day.

Sell
20
ENPH alert for Jun 18

Enphase Energy [ENPH] is up 3.24% over the past day.

Sell
26
FSLR alert for Jun 18

First Solar [FSLR] is up 0.35% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock